Bacteriophage T4 Vaccine Platform for Next-generation Influenza Vaccine Development

Mengling Li, Pengju Guo, Cen Chen, Helong Feng, Wanpo Zhang, Changqin Gu, Guoyuan Wen, Venigalla B. Rao, Tao Pan

Introduction

Influenza remains a persistent global health threat, characterized by its ability to rapidly evolve through a process known as antigenic drift. This variability necessitates the annual reformulation of seasonal vaccines, which primarily target the highly mutable "head" of the hemagglutinin (HA) protein. To overcome this cycle, researchers are pursuing "universal" influenza vaccines that target conserved viral regions—parts of the virus that remain unchanged across different strains.

A primary candidate for such a vaccine is the extracellular domain of matrix protein 2 (M2e). However, M2e is a small peptide with naturally low immunogenicity, often failing to trigger a robust immune response without complex chemical additives. A recent study provides a proof-of-concept for a next-generation solution: a modular vaccine platform using the bacteriophage T4 to display M2e at record-breaking densities.

The T4 "Plug-and-Play" Platform

The researchers leveraged the unique structural biology of the Bacteriophage T4, a virus that infects E. coli, to create a high-density Virus-Like Particle (VLP). The T4 capsid (120 × 90 nm) features two non-essential outer proteins: Hoc (Highly antigenic outer capsid protein) and Soc (Small outer capsid protein).

Using a "Lego-like" assembly approach, the team engineered a mutant T4 phage lacking these proteins. They then produced a fusion protein consisting of Soc (acting as the molecular "glue") and 3M2e—three tandem copies of M2e derived from human, swine, and avian influenza strains. Because these components are produced separately in E. coli and assembled in vitro through simple incubation, the platform offers a rapid, scalable alternative to traditional egg-based vaccine manufacturing.

Key Insights: Density and Natural Adjuvancy

The study identified two critical factors that drive the vaccine's efficacy:

  1. Unprecedented Density: The T4 platform achieved a display of over 1,280 M2e molecules per capsid. This high-density, repetitive pattern mimics the structural characteristics of natural pathogens, which the human immune system is evolutionarily primed to recognize as a threat.
  2. Self-Adjuvanting Properties: Most vaccines require an added chemical adjuvant (like alum) to stimulate the immune system. In this platform, the T4 phage itself acts as a "natural adjuvant," stimulating innate immune pathways and ensuring the antigen is delivered directly to antigen-presenting cells.

Experimental Results

The vaccine's performance was evaluated in BALB/c mice challenged with a lethal dose of the H1N1 (PR8) virus. The results demonstrated a level of protection rarely seen in M2e-based candidates:

  • 100% Survival: All mice immunized with the T4-3M2e nanoparticles survived the lethal challenge.
  • Zero Morbidity: Unlike previous studies where surviving mice still suffered significant illness, the T4-3M2e group showed no weight loss and minimal lung pathology.
  • Robust Immune Response: The vaccine induced M2e-specific IgG titers of approximately 4 × 10⁵, significantly higher than soluble M2e. Furthermore, the vaccine induced a balanced Th1 and Th2 response, which is essential for both clearing viral infections and maintaining long-term antibody production.

Limitations and Future Outlook

While the vaccine provided complete systemic protection, it did not induce secretory IgA in the respiratory tract, which serves as the first line of defense against influenza. Future iterations may explore intranasal delivery to trigger this mucosal immunity.

Additionally, the researchers noted that the "huge room" on the T4 capsid could be used to simultaneously display other conserved targets, such as the HA-stalk or nucleoprotein (NP). This modularity suggests that the T4 platform could eventually host a multi-antigen cocktail, providing an even more formidable defense against future influenza pandemics. Given that all components can be mass-produced in E. coli in a short timeframe, this platform represents a significant step forward in pandemic preparedness.

Summary updated

Abstract

Abstract Developing influenza vaccines that protect against a broad range of viruses is a public health priority, and several conserved viral proteins or domains have been identified as promising targets for such vaccine development. However, none of the targets is immunogenic, and vaccine platforms that can incorporate multiple antigens with enhanced immunogenicity are desperately needed. In this study, we provided proof-of-concept for the development of next-generation influenza vaccine using T4 phage virus-like particle (VLP) platform. With extracellular domain of influenza matrix protein 2 (M2e) as a readout, we showed that more than 1,280 M2e molecules can be assembled on a 120×90 nanometer phage capsid to form T4-M2e VLPs, which are highly immunogenic and induced complete protection against influenza virus challenge without any addition adjuvant. Potentially, additional conserved antigens or molecular adjuvants could be incorporated into the T4-M2e VLPs to customize influenza vaccines to address different issues. All the components of T4 VLP vaccines can be mass-produced in E. coli in a short time, therefore, providing a rapid approach to deal with the potential influenza pandemic.
BibTeX
@inproceedings{li2021bacteriophage,
  author = {Mengling Li and Pengju Guo and Cen Chen and Helong Feng and Wanpo Zhang and Changqin Gu and Guoyuan Wen and Venigalla B. Rao and Tao Pan},
  title = {{Bacteriophage T4 Vaccine Platform for Next-generation Influenza Vaccine Development}},
  booktitle = {Frontiers in Immunology},
  year = {2021},
  doi = {10.3389/fimmu.2021.745625},
}
Figure